ABSTRACT Recent studies have emphasized the significance of biomolecular condensates in modulating gene expression through RNA processing and translational control. However, the functional roles of RNA condensates in cell fate specification remains poorly understood. Here, we profiled the coding and non-coding transcriptome within intact biomolecular condensates, specifically P-bodies, in diverse developmental contexts, spanning multiple vertebrate species. Our analyses revealed the conserved, cell type-specific sequestration of untranslated RNAs encoding key cell fate regulators. Notably, P-body contents did not directly reflect active gene expression profiles for a given cell type, but rather were enriched for translationally repressed transcripts characteristic of the preceding developmental stage. Mechanistically, microRNAs (miRNAs) direct the selective sequestration of RNAs into P-bodies in a context-dependent manner, and perturbing AGO2 or alternative polyadenylation profoundly reshapes P-body RNA content. Building on these mechanistic insights, we demonstrate that modulating P-body assembly or miRNA activity dramatically enhances both activation of a totipotency transcriptional program in naïve pluripotent stem cells as well as the programming of primed human embryonic cells towards the germ cell lineage. Collectively, our findings establish a direct link between biomolecular condensates and cell fate decisions across vertebrate species and provide a novel framework for harnessing condensate biology to expand clinically relevant cell populations.

Prenylnaringenin (PN) compounds, namely 8-prenylnaringenin (8-PN), 3’-prenylnaringenin (3’-PN), and 6-prenylnaringenin (6-PN), are reported to have several interesting bioactivities. This study aimed to validate a biosynthetic pathway for de novo production of PN in Escherichia coli . A previously optimized E. coli chassis capable of efficiently de novo producing naringenin was used to evaluate eleven prenyltransferases (PTs) for the production of PN compounds. As PT reaction requires dimethylallyl pyrophosphate (DMAPP) as extended substrate that has limited availability inside the cells, clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 12a (Cas12a) (CRISPR-Cas12a) was used to construct ten boosted DMAPP-E . coli strains. All the PTs, in combination with the naringenin biosynthetic pathway, were tested in these strains. Experiments in 96-well deep well plates identified twelve strains capable of producing PN. E. coli M-PAR-121 with the integration of the 1-deoxy-D-xylulose-5-phosphate synthase (DXS) gene from E. coli ( Ec DXS) into the lacZ locus of the genome ( E. coli M-PAR-121: Ec DXS) expressing the soluble aromatic PT from Streptomyces roseochromogenes (CloQ) and the naringenin biosynthetic pathway was selected as the best producer strain. After optimizing the production media in shake flasks, 160.57 µM of 3’-PN, 4.4 µM of 6-PN, and 2.66 µM of 8-PN were obtained. The production was then evaluated at the bioreactor scale and 397.57 µM of 3’-PN (135.33 mg/L) and 25.61 µM of 6-PN (8.72 mg/L) were obtained. To the best of our knowledge, this work represents the first report of de novo production of PN compounds using E. coli as a chassis.

Cas9 provides a powerful tool to interrogate DNA repair and to introduce targeted genetic modifications. However, a major challenge of Cas9-based editing in human embryos is the occurrence of chromosomal abnormalities caused by Cas9 cleavage. Furthermore, mosaicism - different genetic outcomes in different cells, prevent accurate genotyping using a single embryo biopsy. Through timed analysis of editing outcomes during the first cell cycle and timed inhibition of Cas9 using AcrIIA4, we show that most edits occur at least 12 hours post Cas9 injection and therefore after the first S-phase. This timing limits the ability to achieve uniform editing across cells. We found that segmental chromosomal abnormalities and the consequential loss of heterozygosity are common at Cas9 cleavage sites throughout the genome, including at MYBPC3 and at CCR5 loci, for which this has not previously been reported. Surprisingly, inhibiting Cas9 activity 8-12 hours before mitosis does not eliminate chromosomal aneuploidies. This suggests that double-strand break (DSB) repair in human embryos is exceedingly slow, with breaks remaining unrepaired for many hours. Thus, the timing of DSB induction and repair relative to the first S-phase and the first mitosis is intrinsically limiting to preventing mosaicism and maintaining genome stability in embryonic gene editing.

ABSTRACT RNA-guided CRISPR nuclease Cas9 cannot reliably differentiate between single nucleotide variations (SNVs) of targeted DNA sequences determined by their guide RNA (gRNA): they typically exhibit similar nuclease activities at any of those variations, unless the variation occurs with specific sequence contexts known as protospacer adjacent motifs (PAMs). Our approach, “TOP-SECRETS,” generates gRNA variants that allow Cas9 ribonucleoproteins (RNPs) to reliably discriminate between healthy and disease-associated SNVs outside of PAMs.

CRISPR-Cas9 guide-RNA design tools can be used to identify guide-RNAs that target single human genomic loci. However, these approaches limit their effect to a single locus. Here, we generate a database of potential individual guide-RNAs that target multiple sites in the genome at once. All guide-RNAs in this database are curated with on- and off-target quantification and enrichment scores for genomic elements such as gene elements, regulatory elements, repetitive elements, and transcription factor motifs. This tool enables rationale mass targeting of genomic loci with a single guide for functional studies. We created a web-app for user-friendly guide-RNA selection ( https://modreklab.shinyapps.io/guiderna/ ).

SUMMARY ARID1A is a subunit of the BAF chromatin remodelling complex that is frequently mutated in cancer. It is challenging to predict how ARID1A loss impacts cancer therapy response because it participates in many different cellular pathways. G quadruplex (G4) binding ligands, such as pyridostatin, have shown anticancer effects, but the pathways and genetic determinants involved in the response to G4 ligands are still not fully understood. Here, we show that ARID1A deficient cells are selectively sensitive to pyridostatin when compared with isogenic controls. Sensitivity to pyridostatin was apparent in ovarian and colorectal cancer cell line models, and in vivo studies suggest that G4 ligands hold promise for treating ARID1A deficient cancers. While we find that ARID1A impacts on pyridostatin-induced transcriptional responses, we find that pyridostatin-mediated toxicity in ARID1A-deficient cells is driven by defective DNA repair of topoisomerase-induced breaks. We show that ARID1A-deficient cells are unable to efficiently accumulate non-homologous end joining proteins on chromatin following pyridostatin exposure. These data uncover a role for ARID1A in the cellular response to G4 ligands, and link remodelling to G4 ligand-induced transcriptional and DNA damage responses.

Suberin deposition in the root endodermis is critical for plant nutrient acquisition and environmental adaptation. Here, we used an unbiased forward genetic approach based on natural variation across 284 Arabidopsis thaliana accessions to identify novel regulators of suberization. This screen revealed striking diversity in suberin levels and patterns, uncovering broader roles for suberin beyond those observed in the reference accession Col-0. A genome-wide association study pinpointed SUBER GENE1 ( SBG1 ), a previously uncharacterized gene encoding a 129-amino acid protein, as a key regulator of suberin deposition. SBG1 acts through physical interaction with type one protein phosphatases (TOPPs) via conserved SILK and RVxF motifs. Disrupting this interaction abolishes SBG1 function, while topp mutants exhibit enhanced endodermal suberization, mirroring SBG1 overexpression. Our findings uncover a previously unknown regulatory module linking suberin formation to TOPP activity and ABA signaling and provide a framework for improving plant stress resilience through targeted manipulation of root barrier properties.

Cancer therapy has evolved dramatically over the past few decades, progressing from traditional treatments such as surgery, chemotherapy, and radiation therapy to more advanced approaches that target the cellular and molecular mechanisms underlying cancer. Understanding these mechanisms is crucial for developing more effective. While surgery, chemotherapy, and radiation therapy remain the cornerstones of cancer treatment, they are often associated with significant side effects and limited specificity. These treatments work by targeting rapidly dividing cells, but they cannot distinguish between cancerous and normal cells, leading to collateral damage. Cancer is fundamentally a disease of cellular and genetic dysregulation. Understanding the cellular and molecular mechanisms that drive cancer progression is essential for developing targeted therapies that can more precisely attack cancer cells while sparing normal cells. Signal transduction pathways regulate various cellular processes, including growth, differentiation, and survival. In cancer, these pathways are often dysregulated, leading to aberrant cell behavior. For example, the PI3K/AKT/mTOR pathway is frequently activated in cancer, promoting cell growth and survival. Combining different types of therapies can enhance their effectiveness and overcome resistance. For example, combining targeted therapies with immunotherapy or traditional treatments can lead to better outcomes. Researchers are continually exploring new combinations to find the most effective strategies. The field of cancer therapy is rapidly evolving, with ongoing research into new molecular targets, biomarkers for early detection, and strategies to overcome resistance. Advances in technologies such as CRISPR gene editing, artificial intelligence, and personalized medicine are poised to revolutionize cancer treatment. In conclusion, understanding the cellular and molecular mechanisms of cancer is crucial for developing more effective and less toxic therapies. While traditional treatments have their limitations, targeted therapies and new approaches offer hope for better outcomes and improved quality of life for cancer patients. Continued research and innovation are essential to conquer this complex and formidable disease.

Bacteria can encode dozens of different immune systems that protect cells from infection by mobile genetic elements (MGEs). Interestingly, MGEs may also carry immune systems, such as CRISPR-Cas, to target competitor MGEs, but it is unclear when this is favoured by natural selection. Here, we develop and test novel theory to analyse the outcome of competition between plasmids when one carries a CRISPR-Cas system that targets the other plasmid. Our model and experiments reveal that plasmid-borne CRISPR-Cas is beneficial to the plasmid carrying it when the plasmid remains in its host. However, CRISPR-Cas is selected against when the plasmid carrying it transfers horizontally, if the competitor plasmid encodes a toxin-antitoxin (TA) system that elicits post-segregational killing. Consistent with a TA barrier to plasmid-borne CRISPR-Cas, a bioinformatic analysis reveals that naturally occurring CRISPR-Cas-bearing plasmids avoid targeting other plasmids with TA systems. Our work shows how the benefit of plasmid-borne CRISPR-Cas is severely reduced against TA-encoding competitor plasmids, but only when plasmid-borne CRISPR-Cas is horizontally transferred. These findings have key implications for the distribution of prokaryotic defenses and our understanding of their role in competition between MGEs, and the utility of CRISPR-Cas as a tool to remove plasmids from pathogenic bacteria.

Abstract Neurodevelopmental disorders associated with epilepsy are typically linked to postnatal dysfunction of synaptic proteins and ion channels, yet increasing evidence suggests a role for these proteins before birth. The voltage-gated sodium channel Nav1.1, encoded by SCN1A , is well studied postnatally. SCN1A mutations result in a broad range of neurological phenotypes including developmental and epileptic encephalopathies (DEEs including Dravet syndrome, DS) and fetal lethality. Here, we investigated the role of SCN1A dysfunction in early corticogenesis. By integrating data from DS patient-derived forebrain models, a DS mouse model, and DS post-mortem tissue, we report altered G2/M cell cycle transition, with a shift towards earlier neurogenic fate commitment. These changes lead to altered cortical specification at birth and throughout life. The early developmental roles of Nav1.1 complement the well-known postnatal roles in neuronal excitability. These discoveries reveal new insights into the DS pathogenesis and a new non-canonical role for Nav1.1 in early corticogenesis.

Abstract Probiotics ( lactic acid bacteria ) are widely used as microbial feed additives in livestock production and play an important role in preventing and treating animal diarrhea as well as regulating host immune function. In this study, lactic acid bacteria were isolated from the fresh feces of healthy adult female sheep, and their biological characteristics were analyzed. Based on phylogenetic analysis, strain SSF2 was identified as Pediococcus pentosaceus . SSF2 exhibited tolerance to acid, bile salt concentrations, and simulated artificial gastrointestinal environments. The hemolysis test for SSF2 was negative, it was sensitive to commonly used antibiotics, and it demonstrated significant antibacterial and antioxidant activities, indicating its excellent probiotic potential. Whole-genome sequencing (WGS) was performed using the HiSeq 2500 platform and the PacBio system to explore the genetic characteristics of SSF2. The genome was revealed to consist of a circular chromosome and two plasmids, with sizes of 1,785,410 bp, 10,618 bp, and 57,766 bp, and GC contents of 37.23%, 34.95%, and 40.98%, respectively. The genome was predicted to contain five genomic islands, six prophages, and a potential CRISPR gene editing sequence. Functional annotation through databases such as COG, GO, and KEGG revealed that most genes are related to carbon metabolism, protein and amino acid metabolism, nucleotide metabolism, and membrane transport processes. This study indicates that an in-depth understanding of the functionality and genetic characteristics of Pediococcus pentosaceus SSF2 may enable the potential application of this strain in sheep feed supplements.

Summary Integrin adhesion complexes mediate cell-extracellular matrix (ECM) interactions and undergo dynamic remodelling to regulate cell adhesion and migration. Here, we demonstrate that tensin 1 (TNS1), a multidomain adhesion adaptor protein linking active integrins with the actin cytoskeleton, undergoes phase separation in cells. Endogenous TNS1 condensates are formed upon focal adhesion disassembly or limited integrin–ECM engagement in both 2D and 3D environments, acting as reservoirs for inactive adhesion proteins. Combining functional experimental approaches with phosphoproteomics, we identify the TNS1 intrinsically disordered region as the main driver of TNS1 condensation and demonstrate a negative regulatory role of phosphorylation on condensate assembly upon activation of stress-responsive kinases. Finally, we confirm the functional effects of phosphorylation-dependent TNS1 condensation on adhesion dynamics and cell migration. Together, our findings highlight TNS1 condensation as a regulatory mechanism controlling local availability of inactive adhesion proteins, with direct implications on adhesion dynamics and cell behaviour.

METTL9 is an enzyme catalysing N1-methylation of histidine residues (1MH) within eukaryotic proteins. Given its high expression in vertebrate nervous system and its potential association with neurodevelopmental delay, we dissected Mettl9 role during neural development. We generated three distinct mouse embryonic stem cell lines: a complete Mettl9 knock-out (KO), an inducible METTL9 Degron and a line endogenously expressing a catalytically inactive protein, and assessed their ability to undergo neural differentiation. In parallel, we down-regulated mettl9 in Xenopus laevis embryos and characterised their neural development. Our multi-omics data indicate that METTL9 exerts a conserved role in sustaining vertebrate neurogenesis. This is largely independent of its catalytic activity and occurs through modulation of the secretory pathway. METTL9 interacts with key regulators of cellular transport, endocytosis and Golgi integrity; moreover, in Mettl9KO cells Golgi becomes fragmented. Overall, we discovered the first developmental function of Mettl9 and linked it to a 1MH-independent pathway, namely, the maintenance of the secretory system, which is essential throughout neural development.

Development of new and improved tuberculosis (TB) chemotherapies is hampered by antibiotic resistance and drug tolerance by Mycobacterium tuberculosis ( Mtb ). Phenotypic drug tolerance, a phenomenon where Mtb populations can temporarily survive therapeutic antibiotic concentrations, represents a significant hurdle to TB treatment and is indeed one of the factors responsible for prolonged TB therapy. Assays that can identify compounds with improved efficacy against drug tolerant Mtb are urgently required to improve TB treatment regimens. Here, we report the development of a 96-well plate assay capable of identifying anti- Mtb drugs with activity against drug tolerant Mtb in physiologically relevant intracellular environments within macrophages. Primary murine macrophages modified either by immunological activation or specific CRISPR/Cas9 gene knockouts to generate tolerance-inducing environments were infected with an Mtb strain constitutively expressing luciferase. Following drug exposure, differences in bacterial survival were measured by bacterial outgrowth after lysis of the host macrophages. By monitoring Mtb luciferase in infected macrophages before, during and after drug treatment, we confirmed earlier observations that host immune stresses trigger induction of drug tolerance. However, while host stresses induced tolerance against some anti-TB compounds, the same host stresses were synergistic with other anti-TB drugs. Our assay provides the ability to profile the activities of anti-TB drugs on bacteria in intracellular host environments which is critical to the rational design of drug combinations that provide optimal coverage of the Mtb sub-populations in the infected host. Author summary TB treatment is a lengthy process which at minimum takes 6-9 months in cases of drug sensitive Mtb . Long TB treatments are in part, due to drug tolerance phenotypes in the bacterial population which can be a result of immune related stresses on the bacteria in the infected host cells. We used this knowledge to develop a luciferase-based assay which can be used to screen, optimize and discriminate anti-TB drugs with enhanced activity against drug tolerant Mtb inside the infected host cells. Primary murine macrophages were modified either by cytokine activation or genetic knockout of certain host genes to mimic immune related stresses experienced by the bacteria in vivo . By infecting the modified macrophages with an Mtb strain expressing luciferase followed by drug addition, our assay was able to confirm that immune related stress induce drug tolerance to Mtb , and that the drug tolerance phenotypes are unique to certain drug classes consistent with their known mode of action. The assay provides an important addition to anti-TB drug discovery by providing a means to readily screen new drugs and drug combinations that display improved activity in tolerance inducing environments in a physiologically relevant context.

The protein tyrosine phosphatases (PTPs) TCPTP, PTPN22, and SHP1 are critical regulators of the activating phosphotyrosine (pY) site on the initiating T cell kinase, Lck Y394. Still, the broader implications of these phosphatases in T cell receptor (TCR) signalling and T cell biology remain unclear. By combining CRISPR/Cas9 gene editing and mass spectrometry, we evaluate the protein- and pY-level effects of TCPTP, PTPN22, and SHP1 in the Jurkat T cell model system. We find that deletion of each phosphatase corresponds to unique changes in the proteome of T cells, with few large-scale changes to TCR signalling proteins. Notably, PTPN22 and SHP1 deletions have opposing effects on pY abundance globally, while TCPTP deletion modestly elevates pY levels. Finally, we show that TCPTP is indirectly involved in Erk1/2 positive feedback to the TCR. Overall, our work provides evidence for alternative functions of three T cell phosphatases long thought to be redundant.

Summary Melanocytes reside in diverse microenvironments that influence their susceptibility to oncogenic transformation, however, studying rare melanoma subsets has been hindered by the lack of suitable animal models. We developed a primary, immune-competent zebrafish model to study uveal melanoma (UM), utilizing choroidal-targeted injection and electroporation of plasmids containing human GNAQ Q209L and CRISPR/Cas9 cassettes for tumor suppressor gene deletion. Single-cell transcriptional profiling of genetically identical eye- and skin-derived tumors revealed distinct oncogenic pathways, highlighting the importance of studying melanoma subtypes in their correct anatomical context. Additionally, we identified a population of tfec - and pax3a -expressing melanocyte progenitor cells in mitfa -deficient embryos and adult zebrafish eyes, which were highly susceptible to GNAQ-driven transformation. While previous studies have linked mitfa deficiency to accelerated UM onset, our findings suggest that an expanded progenitor population in mitfa -deficient animals drives this susceptibility. Our study establishes a critical role for MITF-independent melanocyte progenitors in UM pathogenesis. Highlights Choroid-targeted injection and electroporation of oncogenic GNAQ induces uveal melanoma in adult zebrafish. Germline loss of mitfa leads to expanded mitfa -independent melanocyte progenitor cells which are highly susceptible to GNAQ-driven transformation. Oncogenic BRAF and GNAQ transform molecularly and developmentally distinct subpopulations of cells within the melanocyte lineage. Abstract Figure Graphical Abstract

Background: /Objectives: Notable similarities in lipid metabolism exist between human and golden Syrian hamster relative to most other rodents. A model for β-thalassemia in hamster was sought via knocking out the hemoglobin β-chain (HBB) gene. There are two HBB genes, as well as seven β-like alleles, predicted in the hamster genome, yet none have been functionally characterized. Methods: To develop a β-thalassemia hamster model and genetically interrogate the functions of the HBB genes in the hamster, we employed CRISPR/Cas9-mediated gene targeting technique and successfully knocked out one of the two hamster HBB genes. Results: Surprisingly, mass spectrometry analysis of the hemolysates from wild type, heterozygous, and homozygous knockout (KO) hamsters showed no changes in the hemoglobin β-chains at protein level. This indicates that the HBB gene that we chose to target does not code for proteins. Interestingly, lipid oxidation during storage was elevated in leg muscle of homozygous KO female hamsters compared to wild type females (P<0.05). Conclusions: Our study provided a path toward developing a hamster β-thalassemia animal model, and related findings suggest an effect of a non-translated HBB gene on oxidative stress. In addition, mass spectrometry provides a way to quickly identify non-protein-coding-genes in species where genomic/transcriptomic annotation is not fully developed.

CRISPR-Cas adaptive immunity systems provide defense against mobile genetic elements and are often countered by diverse anti-CRISPR (Acr) proteins. The Type IE CRISPR-Cas of Escherichia coli K12 has been a model for structural and functional studies and is a part of the species’ core genome. However, this system is transcriptionally silent, which has fueled questions about its true biological function. To clarify the role of this system in defense, we carried out a census of Acr proteins found in Enterobacterales and identified AcrIE9 as a potent inhibitor of the E. coli K12 Type IE CRISPR-Cas system. While sharing little sequence identity, AcrIE9 proteins from Pseudomonas and Escherichia both interact with the Cas7 subunit of the Cascade complex, thus preventing its binding to DNA. We further show that AcrIE9 is genetically linked to AcrIE10, forming the most widespread anti-CRISPR cluster in Enterobacterales , and this module often co-occurs with a novel HTH-like protein with unusual architecture.

Rice (Oryza sativa L.) is a vital global crop with a predominant presence in Asia, including Thailand. However, it faces a significant threat from bacterial blight disease (BB), primarily caused by Xanthomonas oryzae pv. oryzae (Xoo). This research aims to provide an insights into the genetic virulence and variation of Xoo strains isolated in Thailand. Our phylogenetic analysis unveils that the 20 Thai strains align with the Asian strains, setting them apart from African and USA strains. Remarkably, the Average Nucleotide Identity (ANI) values, in comparison to the Xanthomonas oryzae type strain 35933 (XO35933), consistently exceed 99%. These strains can be classified into three assigned ribosomal sequence types (rST). Our investigation into the pangenome and the phylogenetic relationships of these 20 Xoo genomes reveals a diverse genetic landscape, with the pangenome comprising 11,872 orthologous gene clusters, of which roughly 30% form the core genome. Notably, all of these genomes exhibit the presence of a CRISPR-Cas I-C array, indicative of their adaptive immune mechanisms. All strains belonged to BXO1 type LPS cassette with high identity. Furthermore, our analysis identifies two distinct types of plasmids, namely, Xanthomonas oryzae pv. oryzicola strain GX01 plasmid pXOCgx01 (A46, A57, A83, A112, D, and E) and the Xanthomonas oryzae strain AH28 plasmid pAH28 (A97). This genomic resource will be valuable for advancing research on surveillance, prevention, management, and comparative studies of this critical pathogen in the future.

Foraging is essential for sustenance and well-being of all organisms. The transition from well-fed to food-deprived conditions in C. elegans triggers a localized exploration of the environment characterized by frequent reorientations. However, over time the cumulative frequency of these reorientations decreases, facilitating the transition to global search behaviour. To investigate the genetic regulation of foraging in C. elegans , we conducted a screen of neuropeptide mutants and identified several candidates involved in modulating this behaviour. Among these, neuropeptide FLP-15 emerged as a key regulator of both local and global search behaviours. Our observations revealed that FLP-15 regulates the frequency and duration of reversals during foraging. Further investigation indicated that FLP-15 is expressed in and functions through the I2 pharyngeal neuron via the G-protein coupled receptor NPR-3. Mutants lacking either flp-15 or npr-3 displayed a significant decrease in reversal frequency during local search behaviours. Interestingly, unlike wild-type animals, the reversal frequency in flp-15 and npr-3 mutants did not decrease over time. This study also describes the expression pattern of NPR-3, in a subset of head neurons, predominantly comprising of dopaminergic neurons. This expression pattern highlights a potential link between neuropeptide signalling and dopaminergic modulation of behaviour. Finally, exogenous dopamine supplementation assays revealed that FLP-15 may regulate foraging by modulating dopamine transmission, highlighting a novel neuropeptide-dopamine interaction involved in the control of foraging behaviours.

ABSTRACT Non-viral gene editing offers a practical alternative to viral delivery for durable biologics production. Clinical trials have shown that adeno-associated virus encoding broadly neutralizing antibodies can protect against HIV, but result in limited, short-lived responses. The development of non-viral gene editing approaches in hematopoietic stem and progenitor cells holds promise for long-term antibody production. In this study, we evaluated CRISPR/Cas9 and CRISPR/Cas12a for gene knock-in at the immunoglobulin heavy chain locus in non-human primate hematopoietic stem and progenitor cells. Delivering the nuclease as a protein alongside a custom DNA template, we optimized editing with Cas12a and demonstrated higher knock-in efficiency and fewer non-specific edits than Cas9. Transplantation of edited non-human primate hematopoietic stem and progenitor cells into MISTRG mice led to engraftment, B cell differentiation, and transgene expression of a reporter transgene or anti-HIV antibody after HIV immunization with detectable anti-HIV antibody titers in peripheral blood circulation. These findings demonstrate the feasibility of using non-viral gene editing in HSPC as a potential strategy for sustained biologics production in the treatment of chronic diseases such as HIV. Future work will assess the efficacy of this model in a non-human primate model of HIV infection.

CRISPR–Cas9 gene editing holds transformative promise for genetic therapies, but is hindered by off-target effects that undermine its precision and safety. To address this, we developed CRISMER, a hybrid deep-learning architecture that uses multi-branch convolutional neural networks to extract k-mer features and transformer blocks to capture long-range dependencies. This hybrid approach enhances the prediction and optimization of single-guide RNA (sgRNA) designs. CRISMER was trained on Change-seq and Site-seq datasets, using a 20 × 16 sparse one-hot encoding scheme, and evaluated on independent datasets including Circle-seq, Guide-seq, Surro-seq, and TTISS. CRISMER outperformed existing tools, achieving an F1 score of 0.7092 and a PR-AUC of 0.8006 on the CRISPR-DIPOff dataset. It also excelled in measuring sgRNA specificity and optimizing designs for genes, such as PCSK9 and BCL11A, yielding sgRNAs with reduced off-target activity. For example, a G-to-C mutation at position 12 in the sgRNA for PCSK9 and at position 11 for BCL11A led to significant improvements in off-target profiles. Interpretability analysis via integrated gradients confirmed the model’s focus on critical PAM-proximal regions and mismatch patterns. These results demonstrate that CRISMER significantly improves the accuracy and safety of CRISPR-Cas9, advancing its reliability for therapeutic applications.

Abstract ​Spatially resolved in vivo CRISPR screening integrates gene editing with spatial transcriptomics to examine how genetic perturbations alter gene expression within native tissue environments. However, current methods are limited to small perturbation panels and the detection of a narrow subset of protein-coding RNAs. We present Perturb-DBiT, a distinct and versatile approach for the simultaneous co-sequencing of spatial total RNA whole-transcriptome and single-guide RNAs (sgRNAs), base-by-base, on the same tissue section. This method enables unbiased discovery of how genetic perturbations influence RNA regulation, cellular dynamics, and tissue architecture in situ. Applying Perturb-DBiT to a human cancer metastatic colonization model, we mapped large panels of sgRNAs across tumor colonies in consecutive tissue sections alongside their corresponding total RNA transcriptomes. This revealed novel insights into how perturbations affect long non-coding RNA (lncRNA) co-variation, microRNA–mRNA interactions, and global and distinct tRNA alterations in amino acid metabolism linked to tumor migration and growth. By integrating transcriptional pseudotime trajectories, we further uncovered the impact of perturbations on clonal dynamics and cooperation. In an immune-competent syngeneic mouse model, Perturb-DBiT enabled investigation of genetic perturbations within the tumor immune microenvironment, revealing distinct and synergistic effects on immune infiltration and suppression. Perturb-DBiT provides a spatially resolved comprehensive view of how genetic knockouts influence diverse molecular and cellular responses including small and large RNA regulation, tumor proliferation, migration, metastasis, and immune interactions, offering a panoramic perspective on perturbation responses in complex tissues.

The evolution of genome engineering technologies has transformed biomedical research, enabling precise and efficient modification of genetic material Doudna and Charpentier, 2014. Among these, CRISPR-Cas9 stands out as a revolutionary gene-editing tool, though it often requires extensive expertise and technical knowledge Cong et al., 2013; J. G. Doench et al., 2016. We propose GeneFix-AI, an Artificial Intelligence (AI)-driven platform for real-time prediction and correction of genetic mutations in non-human species. Developed using cutting-edge models inspired by recent advances at Harvard and Peking University Chen et al., 2021; Wu et al., 2020, GeneFix-AI integrates machine learning to predict mutations, design optimal guide RNAs, and evaluate editing outcomes. This system aims to automate the CRISPR-Cas9 workflow, making high-precision gene editing more accessible to researchers without extensive molecular biology backgrounds Liu et al., 2019. We present the system architecture, training methodology, and potential impact of GeneFix-AI in democratizing genome editing and accelerating discoveries in genetics.

Abstract Background: CRISPR-Cas9 technology is a powerful tool for precise genome editing and is increasingly applied to correct genetic mutations associated with various diseases, including cancer. This system utilizes a single-guide RNA (sgRNA), typically 20 base pairs long and complementary to the target DNA sequence, to direct the Cas9 nuclease for targeted gene activation (knock-in) or repression (knockout). In recent advancements in cancer immunotherapy, CRISPR-Cas9 has been extensively used to enhance the efficacy of Chimeric Antigen Receptor (CAR) T-cell therapy. The development of universal CAR T cells involves the knockout of key genes such as TRAC (T-cell receptor alpha chain), B2M (Beta-2 microglobulin), and PDCD1 (Programmed cell death protein 1), which improves T-cell persistence, immune evasion, and anti-tumor function. Method: In this study, sgRNAs targeting PDCD1, B2M, and TRAC were designed using nine widely recognized AI-driven bioinformatics tools: CHOPCHOP, CRISPOR, GenScript, Benchling, Cas-Designer, E-CRISP, CRISPR-ERA, CRISPRscan, and ATUM gRNA Tool. These platforms use various algorithms and genomic datasets to predict sgRNA candidates with high on-target activity and minimal off-target effects. The selected sgRNAs were assessed based on criteria including GC content, self-complementarity, and exon targeting. Results: The sgRNA design tools consistently identified high-confidence target sites within exon 1 of the PDCD1, TRAC, and B2M genes. For PDCD1 (PD-1), the sgRNA sequence (5′-CACGAAGCTCTCCGATGTGT-3′) was selected as the most optimal candidate, showing strong consensus across all platforms. Similarly, for TRAC, the sgRNA (5′-TCTCTCAGCTGGTACACGGC-3′) targeting exon 1 was chosen based on its high predicted efficiency and specificity. In the case of B2M, the sgRNA (5′-GAGTAGCGCGAGCACAGCTA-3′) was identified as an ideal target site within exon 1, a region critical for MHC class I expression and immune evasion. These sgRNAs demonstrated favorable characteristics including appropriate GC content, minimal self-complementarity, and low predicted off-target activity. To ensure their functional reliability, all selected sgRNAs were validated through an extensive review of scientific literature and previously published patent data, confirming their utility in gene knockout studies related to CAR T-cell enhancement. Conclusion: Among the tools evaluated, CHOPCHOP, Benchling, and CRISPOR emerged as the most comprehensive, offering robust information on GC content, self-complementarity, exon identification, and detailed off-target predictions. Additionally, this study compiled a list of relevant clinical trials involving gene knockouts of PDCD1, TRAC, and B2M to further support the therapeutic relevance of these targets in CAR T-cell development.